1. |
Canaud B, Cohen EP. Initiation of renal-replacement therapy in the intensive care unit. N Engl J Med, 2016, 375(19): 1901.
|
2. |
Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2012, 2(1): 1-138.
|
3. |
Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care, 2007, 11(4): 218.
|
4. |
中华医学会肾脏病学分会专家组. 连续性肾脏替代治疗的抗凝管理指南. 中华肾脏病杂志, 2022, 38(11): 1016-1024.
|
5. |
MacEwen C, Watkinson P, Winearls C. Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction. Ther Apher Dial, 2015, 19(3): 259-266.
|
6. |
Hatamizadeh P, Tolwani A, Palevsky P. Revisiting filtration fraction as an index of the risk of hemofilter clotting in continuous venovenous hemofiltration. Clin J Am Soc Nephro, 2020, 15(11): 1660-1662.
|
7. |
RENAL Replacement Therapy Study Investigators; Bellomo R, Cass A, et al. Intensity of continuous renal replacement therapy in critically ill patients. N Engl J Med, 2009, 361(17): 1627-1638.
|
8. |
Zhang L, Liao Y, Xiang J, et al. Simplified regional citrate anticoagulation using a calcium-containing replacement solution for continuous venovenous hemofiltration. J Artif Organs, 2013, 16(2): 185-192.
|
9. |
Arnold F, Westermann L, Rieg S, et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol, 2020, 21(1): 486.
|
10. |
Huguet M, Rodas L, Blasco M, et al. Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients. Int J Artif Organs, 2017, 40(12): 676-682.
|
11. |
Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA, 2020, 324(16): 1629-1639.
|
12. |
Ricci Z, Ronco C, Bachetoni A, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care, 2006, 10(2): R67.
|
13. |
Brain M, Winson E, Roodenburg O, et al. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol, 2017, 18(1): 69.
|
14. |
Kleger GR, Fässler E. Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill?. Int J Artif Organs, 2010, 33(3): 139-146.
|
15. |
Kellum JA, Ronco C. The 17th acute disease quality initiative international consensus conference: introducing precision renal replacement therapy. Blood Purif, 2016, 42(3): 221-223.
|
16. |
Neri M, Villa G, Garzotto F, et al. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care, 2016, 20(1): 318.
|
17. |
Uchino S, Fealy N, Baldwin I, et al. Pre-dilution vs. post-dilution during continuous veno-venous hemofifiltration: impact on fifilter life and azotemic control. Nephron Clin Pract, 2003, 94(4): c94-c98.
|
18. |
van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif, 2005, 23(3): 175-180.
|
19. |
Tolwani A. Continuous renal-replacement therapy for acute kidney injury. N Engl J Med, 2012, 367(26): 2505-2514.
|
20. |
Sansom B, Sriram S, Presneill J, et al. Low blood flow continuous veno-venous haemodialysis compared with higher blood flow continuous veno-venous haemodiafiltration: effect on alarm rates, filter life, and azotaemic control. Blood Purif, 2022, 51(2): 130-137.
|
21. |
Cassina T, Villa M, Soldani-Agnello A, et al. Comparison of two regional citrate anticoagulation modalities for continuous renal replacement therapy by a prospective analysis of safety, workload, effectiveness, and cost. Minerva Anestesiol, 2021, 87(12): 1309-1319.
|
22. |
Xu Q, Jiang B, Li J, et al. Comparison of filter life span and solute removal during continuous renal replacement therapy: convection versus diffusion- a randomized controlled trial. Ther Apher Dial, 2022, 26(5): 1030-1039.
|